UNSPSC 51171812: Prochlorperazine

This classification denotes a phenothiazine with the molecular formula C20H24ClN3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YHP6YLT61T, chemically known as 10h-phenothiazine, 2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)- but generally known as prochlorperazine, which bears US NIH Compound Identifier 4917. European Medicines Agency schedules Prochlorperazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10059MIG.

UNSPSC 51171812 Prochlorperazine is a Commodity code that represents pharmaceutical products procured for institutional and government healthcare, criminal justice, and benefit programs. State and local governments buying under this code are acquiring generic pharmaceuticals and over-the-counter products for distribution through state health agencies, correctional departments, multistate cooperative purchasing alliances, and employee benefit programs. The work spans both direct manufacturer relationships and distribution through established wholesalers, with procurement focused on supply chain compliance, pricing transparency, and operational delivery across multiple authorized channels.

Recent activity shows issuing bodies ranging from state health agencies (Texas Health and Human Services Commission) to county criminal justice departments (Collin County Community Supervision and Corrections Department) to multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across participating jurisdictions including Oregon and Minnesota). Representative recent solicitations include the Collin County RFP 2026-327 for offender specimen collection and drug testing services (response due July 23, 2026, with an estimated contract value of $600,000 and a two-year term with three optional one-year renewal periods), the Texas HHS Commission RFI No. HHS0017013 posted April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs before formal procurement, and the MMCAP RFP S1070000015802 issued January 20, 2026 (responses due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products through authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC. The geographic spread centers on Texas and the Upper Midwest (Minnesota and Oregon), with activity reflecting both single-jurisdiction procurement and cooperative purchasing arrangements spanning multiple states and local governments.